TY - JOUR
T1 - Chemotherapy of invasive thymoma
AU - Fornasiero, Adriano
AU - Daniele, Otello
AU - Ghiotto, Cristina
AU - Sartori, Francesco
AU - Rea, Federico
AU - Piazza, Mario
AU - Fiore-Donati, Luciano
AU - Morandi, Paolo
AU - Aversa, Savina M L
AU - Paccagnella, Adriano
AU - Pappagallo, Giovanni L.
AU - Fiorentino, Mario V.
PY - 1990
Y1 - 1990
N2 - Thirty-two patients with stage III or IV invasive thymoma (14 women and 18 men; median age, 40 years) were treated at the Padua Medical Oncology Department from 1977 to 1988. All patients received the following chemotherapy in 4-day courses: 50 mg/m2 of cisplatin intravenously (IV) and 40 mg/m2 of doxorubicin IV on day 1;0.6 mg/m2 of vincristine IV on day 3; and 700 mg/m2 of cyclophosphamide IV on day 4 (ADOC). The courses were repeated every 3 weeks, and toxic effects were tolerable. The radiologically defined overall clinical response rate (complete plus partial response) was 91% with 47% clinical complete remissions; median time to progression was 11 months (range, 0 to 96) and the median estimated (Kaplan-Meier) progression-free interval was 22 months. Five of the 15 clinical complete remissions were pathologically confirmed at thoracotomy. We believe the ADOC regimen qualifies for adjuvant and preoperative treatment of invasive thymoma due to the high complete response and overall response rates.
AB - Thirty-two patients with stage III or IV invasive thymoma (14 women and 18 men; median age, 40 years) were treated at the Padua Medical Oncology Department from 1977 to 1988. All patients received the following chemotherapy in 4-day courses: 50 mg/m2 of cisplatin intravenously (IV) and 40 mg/m2 of doxorubicin IV on day 1;0.6 mg/m2 of vincristine IV on day 3; and 700 mg/m2 of cyclophosphamide IV on day 4 (ADOC). The courses were repeated every 3 weeks, and toxic effects were tolerable. The radiologically defined overall clinical response rate (complete plus partial response) was 91% with 47% clinical complete remissions; median time to progression was 11 months (range, 0 to 96) and the median estimated (Kaplan-Meier) progression-free interval was 22 months. Five of the 15 clinical complete remissions were pathologically confirmed at thoracotomy. We believe the ADOC regimen qualifies for adjuvant and preoperative treatment of invasive thymoma due to the high complete response and overall response rates.
UR - http://www.scopus.com/inward/record.url?scp=0025151098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025151098&partnerID=8YFLogxK
M3 - Article
C2 - 2380761
AN - SCOPUS:0025151098
VL - 8
SP - 1419
EP - 1423
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 8
ER -